Prostate cancer is the most prevalent cancer in US and European men and the second leading cause of cancer death in those populations.
It is somewhat unique in that nearly all patients who succumb to the disease will ultimately develop bone metastasis. Morbidity from bone metastasis-referred to as skeletal-related events, which include fractures, cord compression, radiation to bone, and surgery to bone-leads to significant costs and impaired quality of life. This article reviews three agents and the roles they play in the ever-changing armamentarium of treatments for metastatic castrate-resistant prostate cancer (mCRPC). The potential benefits of these agents are discussed, as well as the continuing use of these agents and their earlier introduction in the patient with progressive mCRPC with bone metastasis.
Written by:
Sieber PR. Are you the author?
Lancaster Urology, Lancaster, PA.
Reference: Rev Urol. 2014;16(1):10-20.
PubMed Abstract
PMID: 24791151
UroToday.com Bone Metastases Section
